Evidence map›Paper›PMID 40233096›Full record

ArticlePLoS neglected tropical diseases2025

Mass drug administration coverage and its determinants for the elimination of onchocerciasis in Ulanga District, Tanzania.

Ambakisye Kuyokwa Mhiche, Dinah Gasarasi, George Kabona, Ally Hussein, Upendo John Mwingira, Ahmed Mohamed Abade

Abstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ambakisye Kuyokwa MhicheResearch Triangle Institute International, Dodoma, Tanzania.ORCID 0009-0006-0644-8342
Dinah GasarasiMuhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
George KabonaNeglected Tropical Diseases Control Program, Ministry of Health, Dodoma, Tanzania.
Ally HusseinTanzania Field Epidemiology and Laboratory Training Program, Ministry of Health, Dar Es Salaam, Tanzania.
Upendo John MwingiraResearch Triangle Institute International, Dodoma, Tanzania.
Ahmed Mohamed AbadeAfrican Field Epidemiology Network (AFENET), Dar Es Salaam, Tanzania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOnchocerciasis remains an important public health problem targeted for elimination in Tanzania. Ulanga District was hyperendemic for onchocerciasis before the intervention, underscoring the need for particularly high coverage in MDA efforts. The district has been implementing MDA through Community Directed Treatment with Ivermectin (CDTI) strategy since 1998. However, there is preliminary evidence of persistent onchocerciasis transmission, which likely sustains the observed high prevalence of Onchocerciasis in both human and vector species. This could be linked to poor treatment coverage. This study was conducted to assess treatment coverage and explore factors that determine drug uptake during MDA program.

methodsA cross-sectional study was conducted in Ulanga District, Morogoro, Tanzania, from April to June 2019. Using multistage cluster sampling, 502 participants were randomly selected and interviewed through a structured questionnaire. Modified Poisson regression analysis was used to identify independent factors affecting MDA uptake.

resultsThe overall response rate was 96% with majority (67%) of respondents being females, and the mean age of the study participants was 37.8 years with a standard deviation (SD) of ± 15 years. The study found that MDA coverage varied across villages: Mawasiliano (68%, CI: 59.3 - 75.6), Uponera (83%, CI; 76.6 - 89.6), Isongo (84.8%, CI: 77.3 - 90.1) and Togo (79%, CI: 70.1 - 85.8). While Uponera and Isongo achieved the WHO-recommended 80% coverage for transmission interruption, Mawasiliano and Togo fell below this threshold. Age significantly influenced drug uptake, with younger individuals (15-24 years) having a lower uptake rate [APR = 2.8, p = 0.008], followed by the 25-34 age group [APR = 2.3, p = 0.04]. Occupation also played a role, as small and medium enterprise (SME) workers [APR = 3.2, p = 0.05] and students [APR = 2.9, p = 0.05] were less likely to participate. Residence duration in the village was a strong predictor of MDA uptake. Individuals living in the village for more than a year were significantly more likely to participate [APR = 2.3, p = 0.00]. Additionally, a lack of awareness about MDA benefits negatively impacted participation, as those uncertain about its benefits were less likely to take the drug [APR = 2.5, p = 0.03]. Similarly, individuals unaware of the correct MDA distribution schedule had lower uptake [APR = 2.5, p = 0.03]. However, those who took Ivermectin for prevention purposes were significantly more likely to participate [APR = 13.4, p = 0.001].

conclusionMDA coverage below the WHO optimally recommended coverage has been demonstrated in the villages studied. This implies low drug uptake, delayed interruption of transmission and Onchocerciasis elimination. The findings highlight the need for targeted interventions to improve MDA coverage by focusing on younger individuals, certain occupational groups, and new residents. Strengthening community engagement, improving health communication, and intensifying biannual MDA efforts are recommended to accelerate Onchocerciasis elimination in the district. It also underscores the need for adopting other effective public health interventions such as community mobilization towards slash and clear of potential breeding sites for Onchocerciasis vector.

Indexed as

Antiparasitic AgentsIvermectinMass Drug AdministrationOnchocerciasisAdolescentAdultAgedAnimalsCross-Sectional StudiesDisease EradicationFemaleHumansMaleMiddle AgedPrevalenceSurveys and QuestionnairesAntiparasitic AgentsIvermectin

Identifiers

PMID40233096
PMCPMC12047752

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.